Calosyn Pharma, Inc. is raising up to $1.24M on StartEngine Primary, LLC in convertible note; in its filing revenue was $0 and it had 3 employees (Form C-U, 2026-03-02).
Calosyn Pharma, Inc. filed a Regulation Crowdfunding offering with the SEC through StartEngine Primary, LLC, with a target of $20K and a maximum of $1.24M. As of November 6, 2026, the offering is past its deadline of February 27, 2026. The company gives its address as Shreveport, LA (Form C/A, December 19, 2025).
Sell to companies like Calosyn Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · What it is: Progress update · C-U
- · Intermediary: StartEngine Primary, LLC · Target: $20K · Maximum: $1.24M · Deadline: 2026-02-27 · Security: Convertible Note · C/A
- · Intermediary: StartEngine Primary, LLC · Target: $20K · Maximum: $1.24M · Deadline: 2025-12-29 · Security: Convertible Note · C
- · What: Private placement (Form D) · Amount as filed: $750K sold of $2M offered · filing
Calosyn Pharma, Inc., based in Shreveport, LA, filed 2 Regulation Crowdfunding offering filings with the SEC, the latest on 2025-12-19, raising through StartEngine Primary, LLC. It set a target of $20K and will accept up to $1.24M. The security offered is convertible note. As of its filings the offering is past its deadline of 2026-02-27. 3 filings in this family are on record for the company.
Terms at a glance
| Target | $20K |
| Maximum it will accept | $1.24M |
| Security | Convertible Note |
| Units at the target | 20,000 |
| Raise above the target | accepted, other |
| Deadline | 2026-02-27 |
| Raising through | StartEngine Primary, LLC |
| What the portal is paid, as filed | 7 - 13 percent |
Check before you invest in Calosyn Pharma, Inc.: who signed the filing and its own figures, free.
Free to see. No signup.
Want the whole picture on Calosyn Pharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Calosyn Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Calosyn Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
The filing does not state a company valuation or a minimum investment; the offering page on StartEngine Primary, LLC shows those. Check both before you invest.
Money raised before
Earlier raises by this company that are on file, with the amounts as filed. A figure for a raise is what the company reported, not a check of what it received.
| Filed | What | Amount as filed | Filing |
|---|---|---|---|
| 2024-03-07 | Private placement (Form D) | $750K sold of $2M offered | filing |
Offering filings
| Filed | Intermediary | Target | Maximum | Deadline | Security | Filing |
|---|---|---|---|---|---|---|
| 2025-12-19 | StartEngine Primary, LLC | $20K | $1.24M | 2026-02-27 | Convertible Note | C/A |
| 2025-09-30 | StartEngine Primary, LLC | $20K | $1.24M | 2025-12-29 | Convertible Note | C |
Financials the company filed
Figures from the C-U filed 2026-03-02, as the company reported them.
| As filed | Most recent fiscal year | Prior fiscal year |
|---|---|---|
| Revenue | $0 | $0 |
| Net income | -$638K | -$768K |
| Total assets | $164K | $155K |
| Cash and equivalents | $147K | |
| Short-term debt | $436K | |
| Long-term debt | $2.36M |
Employees at filing: 3.
Revenue went from $0 to $0. Net loss was $638K, against a loss of $768K the year before. It reported $147K in cash and $2.80M in debt. These are the company's own figures from the Form C-U filed 2026-03-02.
Progress updates
2026-03-02, C-U:
At the close of the offering, the issuer closed on $126,903.04 and 0 number of securities.
People who signed the filing
- Reid Grimes, CEO, Board Member
- David D. Waddell, Board Member, Founder, and Chief Medical Officer
- Richard Babb, Chief Financial Officer, Board Observer and Treasurer
- Ross Pryor Barrett, Board Member
- Joe Lovett, Board Member
Every filing
| Filed | What it is | Filing |
|---|---|---|
| 2026-03-02 | Progress update | C-U |
| 2025-12-19 | Offering amended | C/A |
| 2025-09-30 | Offering | C |
What to check before investing
- Read the offering page on StartEngine Primary, LLC: it states the valuation or cap and the minimum investment, which the SEC filing does not.
- Compare the terms above with the numbers: what does the price imply against revenue of $0?
- Look at who signed the filing and what else they have run (the founder Snapshot below).
- Check the deadline and what happens if the target is missed.
- You cannot easily sell a crowdfunding security; invest only what you can leave tied up.
A crowdfunding round is won in public. FoxPlug turns your commits, deploys and releases into the posts and visuals that keep the story moving while the offering is open.
Build your launch kitRun a Snapshot on Reid Grimes: other companies, roles and the record behind them. Order Full Report from there if you need more.
Snapshot the foundersTools for this story
Each opens in a new tab, filled in for Calosyn Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company raising money from the public under Regulation Crowdfunding has to file with the SEC before the offering opens, and has to raise through a single registered intermediary: a funding portal or a broker-dealer. The first filing, Form C, states how much the company is trying to raise, the most it will accept, the deadline, the security and its price, the intermediary and what the intermediary is paid, and two years of the company's own financial figures.
After that the company files amendments when terms change, progress updates as the raise moves, and an annual report each year until it stops reporting. Every row here is one of those filings, linked to the filing itself, so each figure can be checked at the source. Figures are exactly as the company filed them; where a filing leaves a field blank, so does this page. Nothing here is investment advice, and a filing is the company's own statement, not a verification of it.